BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q4 2025 vs. Q3 2025
How the institutions holding BIO-TECHNE Corp changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 577 | 10 | 586 | +19 |
| Shares | 158.9M | 307.9K | 171.9M | +13.3M (+8.4%) |
| Value | $8.84B | $17.1M | $10.1B | +$1.29B (+14.6%) |
10 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (89)
Institutions that held BIO-TECHNE Corp at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (70)
Institutions that held BIO-TECHNE Corp at the end of Q3 2025 and filed for Q4 2025 without it.
Not filed for Q4 2025 yet (10)
Institutions that held BIO-TECHNE Corp at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Broadcrest Asset Management, LLC | 100,000 | $5.56M |
| Stone Run Capital, LLC | 78,195 | $4.35M |
| Ownership Capital B.V. | 77,257 | $4.30M |
| Synovus Financial Corp | 20,159 | $1.12M |
| CIBC Bancorp USA Inc. | 16,007 | $890.5K |
| Wolverine Trading, LLC | 10,174 | $531.4K |
| Wetherby Asset Management Inc | 5,698 | $317.0K |
| Shell Asset Management Co | 213 | $12.0K |
| Hemington Wealth Management | 137 | $7.00K |
| Guerra Advisors Inc | 45 | $2.50K |